Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)
About this trial
This is an interventional treatment trial for Diabetic Macular Edema (DME) focused on measuring Neovascular "wet" age-related macular degeneration
Eligibility Criteria
Key Inclusion Criteria: Patient must have diabetic macular edema (DME) or neovascular "wet" age-related macular degeneration (nAMD) in the study eye Study eye considered by the retina specialist to be eligible for treatment with 8 mg aflibercept Key Exclusion Criteria: Any active intraocular inflammation or infection in either eye or history of intraocular inflammation or infection after past IVT injections with any agent in either eye Treatment with any IVT injection in the study eye within the 25 days prior to day 1 Intraocular pressure (IOP) >25 mm Hg in the study eye at screening Any intraocular surgery in the study eye at any time during the past 3 months Any prior extended-release therapeutic agent, or ocular drug-release device implantation (approved or investigational, including steroids) in the study eye NOTE: Other protocol Defined Inclusion/Exclusion Criteria Apply
Sites / Locations
Arms of the Study
Arm 1
Experimental
8 mg Dose
Only 1 eye will be selected as the study eye by the investigator. Patients will receive a single dose utilizing the PFS.